A

Acusphere Inc
OTC:ACUS

Watchlist Manager
Acusphere Inc
OTC:ACUS
Watchlist
Price: 0.001 USD 900% Market Closed
Market Cap: 5 USD

Relative Value

ACUS latest financial reports are more than 14 years old.
ACUS doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of ACUS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACUS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
21.4
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
16.4
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
22.8
vs History
vs Industry
Median 3Y
-0
Median 5Y
-0
Industry
2.2
vs History
vs Industry
Median 3Y
2.2
Median 5Y
2.2
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-0.2
Median 5Y
-0.2
Industry
13
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0.1
Industry
16.5
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.3
Industry
15.6
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.3
Industry
18.7
vs History
vs Industry
Median 3Y
1
Median 5Y
1
Industry
1.9

Multiples Across Competitors

ACUS Competitors Multiples
Acusphere Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Acusphere Inc
OTC:ACUS
5 USD 0 -0 -0.2 -0.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
262.7B CHF 4.3 27.9 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
217.7B GBP 5.1 31.3 108.6 158.9
CH
Novartis AG
SIX:NOVN
214B CHF 4.8 18.7 11.8 15.3
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.8 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/S Multiple
Revenue Growth P/S to Growth
US
A
Acusphere Inc
OTC:ACUS
Average P/S: 71.9
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
16.9
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.3
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.3
3%
1.4
UK
AstraZeneca PLC
LSE:AZN
5.1
8%
0.6
CH
Novartis AG
SIX:NOVN
4.8
5%
1
US
Merck & Co Inc
NYSE:MRK
4.2
4%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
5.1
5%
1
IE
E
Endo International PLC
LSE:0Y5F
92.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
US
A
Acusphere Inc
OTC:ACUS
Average P/E: 24.6
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.3
37%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Acusphere Inc
OTC:ACUS
Average EV/EBITDA: 439.8
Negative Multiple: -0.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.6
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Acusphere Inc
OTC:ACUS
Average EV/EBIT: 1 883.5
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.9
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5